PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals

Toxicology

Volumn 278, Issue 3, 2010, Pages 256-267

  Bois, Frédéric Y ^a,b   Jamei, Masoud ^c   Clewell, Harvey J ^d  

^a UNIVERSITÉ DE TECHNOLOGIE DE COMPIÈGNE   (France)

^b INSTITUT NATIONAL DE L ENVIRONNEMENT INDUSTRIEL ET DES RISQUES INERIS   (France)

^c CERTARA UK LIMITED   (United Kingdom)

^d HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

Author keywords

Drug drug interactions; Monte Carlo simulations; PBPK models; Population models; Susceptible populations; Toxicokinetics

Indexed keywords

ENVIRONMENTAL CHEMICAL; XENOBIOTIC AGENT;

BAYES THEOREM; BILIARY EXCRETION; HIDDEN MARKOV MODEL; LIVER METABOLISM; MONTE CARLO METHOD; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL; POPULATION MODEL; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; RISK ASSESSMENT; SKIN ABSORPTION; TISSUE BLOOD FLOW; TOXICOKINETICS; URINARY EXCRETION; XENOBIOTIC METABOLISM;

ANIMALS; DRUG INTERACTIONS; ENVIRONMENTAL POLLUTANTS; HUMANS; MODELS, BIOLOGICAL; MONTE CARLO METHOD; RISK ASSESSMENT;

EID: 78649736009     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2010.06.007     Document Type: Review

References (164)

1. Agoram B., Woltosz W.S., Bolger M.B. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Advanced Drug Delivery Reviews 2001, 50(Suppl. 1):S41-S67.
2. Allen B.C., Covington T.R., Clewell H.J. Investigation of the impact of pharmacokinetic variability and uncertainty on risks predicted with a pharmacokinetic model for chloroform. Toxicology and Applied Pharmacology 1996, 111:289-303.
3. Allen B.C., Hack C.E., Clewell H.J. Use of Markov chain Monte Carlo analysis with a physiologically-based pharmacokinetic model of methylmercury to estimate exposures in US women of childbearing age. Risk Analysis 2007, 27:947-959.
4. Andersen M.E. What do we mean by ... dose?. Inhalation Toxicology 1995, 7:909-915.
5. Andersen M.E., Clewell H.J., Gargas M.L., Smith F.A., Reitz R.H. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. Toxicology and Applied Pharmacology 1987, 87:185-205.
6. Andersen M.E., Reddy M.B., Clewell H.J., Yang R.S. Conclusions and future directions. Physiologically Based Pharmacokinetic Modeling: Science and Applications 2005, 389-399. John Wiley & Sons. M.B. Reddy, R.S. Yang, M.E. Andersen, H.J. Clewell (Eds.).
7. Arias I.M., Che M., Gatmaitan Z., Leveille C., Nishida T., St Pierre M. The biology of the bile canaliculus, 1993. Hepatology 1993, 17:318-329.
8. Artursson P., Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochemical and Biophysical Research Communications 1991, 175:880-885.
9. Barter Z.E., Bayliss M.K., Beaune P.H., Boobis A.R., Carlile D.J., Edwards R.J., Houston J.B., Lake B.G., Lipscomb J.C., Pelkonen O.R., Tucker G.T., Rostami-Hodjegan A. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Current Drug Metabolism 2007, 8:33-45.
10. Barton H.A., Chiu W.A., Setzer W., Andersen M.E., Bailer A.J., Bois F.Y., DeWoskin R.S., Hays S., Johanson G., Jones N., Loizou G., MacPhail R.C., Portier C.J., Spendiff M., Tan Y.-M. Characterizing uncertainty and variability in physiologically-based pharmacokinetic (PBPK) models: state of the science and needs for research and implementation. Toxicological Sciences 2007, 99:395-402.
11. Beal S.L., Sheiner L.B. The NONMEM system. American Statistician 1980, 34:118-119.
12. Beal S.L., Sheiner L.B. Estimating population kinetics. CRC Critical Reviews in Biomedical Engineering 1982, 8:195-222.
13. Berezhkovskiy L.M. Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. Journal of Pharmaceutical Sciences 2004, 93:1628-1640.
14. Bernillon P., Bois F.Y. Statistical issues in toxicokinetic modeling: a Bayesian perspective. Environmental Health Perspectives 2000, 108(Suppl. 5):883-893.
15. Bogen K.T., Spear R.C. Integrating uncertainty and interindividual variability in environmental risk assessment. Risk Analysis 1987, 7:427-436.
16. Bois F.Y. Analysis of PBPK models for risk characterization. Annals of the New York Academy of Sciences 1999, 895:317-337.
17. Bois F.Y. Statistical analysis of Clewell et al. PBPK model of trichloroethylene kinetics. Environmental Health Perspectives 2000, 108(Suppl. 2):307-316.
18. Bois F.Y. Applications of population approaches in toxicology. Toxicology Letters 2001, 120:385-394.
19. Bois F.Y. Physiologically-based modelling and prediction of drug interactions. Basic and Clinical Pharmacology and Toxicology 2010, 106:154-161.
20. Bois F.Y., Diack C. Uncertainty analysis: the Bayesian approach. Quantitative Methods for Cancer and Human Health Risk Assessment 2005, Wiley, New-York. L. Edler, C.P. Kitsos (Eds.).
21. Bois F.Y., Gelman A., Jiang J., Maszle D., Zeise L., Alexeef G. Population toxicokinetics of tetrachloroethylene. Archives of Toxicology 1996, 70:347-355.
22. Bois F.Y., Jackson E.T., Pekari K., Smith M.T. Population toxicokinetic of benzene. Environmental Health Perspectives 1996, 104:1405-1411.
23. Bois F.Y., Paxman D. An analysis of exposure rate effects for benzene using a physiologically based pharmacokinetic model. Regulatory Toxicology and Pharmacology 1992, 15:122-136.
24. Bois F.Y., Smith T., Gelman A., Chang H.-Y., Smith A. Optimal design for a study of butadiene toxicokinetics in humans. Toxicological Sciences 1999, 49:213-224.
25. Bois F.Y., Tozer T.N., Hauck W.W., Chen M.-L., Patnaik R., Williams R.L. Bioequivalence: performance of several measures of extent. Pharmaceutical Research 1994, 11:715-722.
26. Bois F.Y., Tozer T.N., Hauck W.W., Chen M.-L., Patnaik R., Williams R.L. Bioequivalence: performance of several measures of rate. Pharmaceutical Research 1994, 11:966-974.
27. Bois F.Y., Woodruff T.J., Spear R.C. Comparison of three physiologically-based pharmacokinetic models of benzene disposition. Toxicology and Applied Pharmacology 1991, 110:79-88.
28. Bois F.Y., Zeise L., Tozer T.N. Precision and sensitivity analysis of pharmacokinetic models for cancer risk assessment: tetrachloroethylene in mice, rats and humans. Toxicology and Applied Pharmacology 1990, 102:300-315.
29. Bouvier d'Yvoire M., Prieto P., Blaauboer B.J., Bois F.Y., Boobis A., Brochot C., Coecke S., Freidig A., Gundert-Remy U., Gundert-Remy U., Gundert-Remy U., Gundert-Remy U., Hartung T., Jacobs M.N., Lavé T., Leahy D.E., Lennernäs H., Loizou G.D., Meek B.C.P., Rowland M., Spendiff M., Yang J., Zeilmaker M. Physiologically-based kinetic modelling (PBK modelling): meeting the 3Rs agenda - the report and recommendations of ECVAM Workshop 63a. Alternatives to Laboratory Animals 2007, 35:661-671.
30. Brochot C., Bessoud B., Balvay D., Cuénod C.-A., Siauve N., Bois F.Y. Evaluation of antiangiogenic treatment effects on tumors microcirculation by Bayesian physiological pharmacokinetic modeling and magnetic resonance imaging. Magnetic Resonance Imaging 2006, 24:1059-1067.
31. Canaparo R., Finnstrom N., Serpe L., Nordmark A., Muntoni E., Eandi M., Rane A., Zara G.P. Expression of CYP3A isoforms and P-glycoprotein in human stomach, jejunum and ileum. Clinical and Experimental Pharmacology & Physiology 2007, 34:1138-1144.
32. Chandra P., Brouwer K.L. The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharmaceutical Research 2004, 21:719-735.
33. Chiu W.A., Bois F.Y. Revisiting the population toxicokinetics of tetrachloroethylene. Archives of Toxicology 2006, 80:386.
34. Cleek R.L., Bunge A.L. A new method for estimating dermal absorption from chemical exposure. 1. General approach. Pharmaceutical Research 1993, 10:497-506.
35. Clewell H.J., Andersen M.E. Use of physiologically based pharmacokinetic modeling to investigate individual versus population risk. Toxicology 1996, 111:315-329.
36. Clewell H.J., Crump K.S., Gentry P.R., Shipp A.M. Site-specific reference dose for methylmercury for fish-eating populations. Fuel Processing Technology 2000, 65-66:43-54.
37. Clewell H.J., Gearhart J.M., Gentry P.R., Covington T.R., VanLandingham C.B., Crump K.S., Shipp A.M. Evaluation of the uncertainty in an oral reference dose for methylmercury due to interindividual variability in pharmacokinetics. Risk Analysis 1999, 19:547-558.
38. Clewell H.J., Gentry P.R., Covington T.R., Sarangapani R., Teeguarden J.G. Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Toxicological Sciences 2004, 79:381-393.
39. Clewell H.J., Gentry P.R., Gearhart J.M., Covington T.R., Banton M.I., Andersen M.E. Development of a physiologically based pharmacokinetic model of isopropanol and its metabolite acetone. Toxicological Sciences 2001, 63:160-172.
40. Clewell H.J., Jarnot B.M. Incorporation of pharmacokinetics in non-carcinogenic risk assessment: example with chloropentafluorobenzene. Risk Analysis 1994, 14:265-276.
41. Covington T.R., Gentry P.R., Van Landingham C.B., Andersen M.E., Kester J.E., Clewell H.J. The use of Markov chain Monte Carlo uncertainty analysis to support a Public Health Goal for perchloroethylene. Regulatory Toxicology and Pharmacology 2007, 47:1-18.
42. David R.M., Clewell H.J., Gentry P.R., Covington T.R., Morgott D.A., Marino D.J. Revised assessment of cancer risk to dichloromethane II. Application of probabilistic methods to cancer risk determinations. Regulatory Toxicology and Pharmacology 2006, 45:55-65.
43. Davidian M., Gallant A.R. Smooth nonparametric maximum likelihood estimation for population pharmacokinetics, with application to quinidine. Journal of Pharmacokinetics and Biopharmaceuticals 1992, 20:529-556.
44. Davies B., Morris T. Physiological parameters in laboratory animals and humans. Pharmaceutical Research 1993, 10:1093-1095.
45. Davis S.S., Hardy J.G., Fara J.W. Transit of pharmaceutical dosage forms through the small intestine. Gut 1986, 27:886-892.
46. de la Grandmaison G.L., Clairand I., Durigon M. Organ weight in 684 adult autopsies: new tables for a Caucasoid population. Forensic Science International 2001, 119:149-154.
47. Dresser M.J., Leabman M.K., Giacomini K.M. Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. Journal of Pharmaceutical Sciences 2001, 90:397-421.
48. Dressman J.B., Amidon G.L., Fleisher D. Absorption potential: estimating the fraction absorbed for orally administered compounds. Journal of Pharmaceutical Sciences 1985, 74:588-589.
49. Edginton A.N., Schmitt W., Willmann S. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clinical Pharmacokinetics 2006, 45:1013-1034.
50. Edginton A.N., Theil F.P., Schmitt W., Willmann S. Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opinion on Drug Metabolism & Toxicology 2008, 4:1143-1152.
51. Fadda H., McConnell E., Short M., Basit A. Meal-induced acceleration of tablet transit through the human small intestine. Pharmaceutical Research 2009, 26:356-360.
52. Fallingborg J., Christensen L.A., Ingeman-Nielsen M., Jacobsen B.A., Abildgaard K., Rasmussen H.H. pH-profile and regional transit times of the normal gut measured by a radiotelemetry device. Alimentary Pharmacology & Therapeutics 1989, 3:605-613.
53. Farahmand S., Maibach H.I. Transdermal drug pharmacokinetics in man: interindividual variability and partial prediction. International Journal of Pharmaceutics 2009, 367:1-15.
54. Farahmand S., Maibach H.I. Estimating skin permeability from physicochemical characteristics of drugs: a comparison between conventional models and an in vivo-based approach. International Journal of Pharmaceutics 2009, 375:41-47.
55. Fiserova-Bergerova V. Gases and their solubility: a review of fundamentals. Modeling of Inhalation Exposure to Vapors: Uptake, Distribution, and Elimination 1983, 3-28. CRC Press, Boca Raton, Florida. F. Fiserova-Bergerova (Ed.).
56. Fiserova-Bergerova V., Diaz M.L. Determination and prediction of tissue-gas partition coefficients. International Archives of Occupational and Environmental Health 1986, 58:75-87.
57. Fiserova-Bergerova V., Vlach J., Cassady J.C. Predictable "individual differences" in uptake and excretion of gases and lipid soluble vapour - simulation study. British Journal of Industrial Medicine 1980, 37:42-49.
58. Galetin A., Brown C., Hallifax D., Ito K., Houston J.B. Utility of recombinant enzyme kinetics in prediction of human clearance: impact of variability, CYP3A5, and CYP2C19 on CYP3A4 probe substrates. Drug Metabolism and Disposition 2004, 32:1411-1420.
59. Garrett E.R. Pharmacokinetics and clearances related to renal processes. International Journal of Clinical Pharmacology and Biopharmacy 1978, 16:155-172.
60. Gearhart J.M., Mahle D.A., Greene R.J., Seckel C.S., Flemming C.D., Fisher J.W., Clewell H.J. Variability of physiologically based pharmacokinetic (PBPK) model parameters and their effects on PBPK model predictions in a risk assessment for perchloroethylene (PCE). Toxicology Letters 1993, 68:131-144.
61. Gelman A., Bois F.Y., Jiang J. Physiological pharmacokinetic analysis using population modeling and informative prior distributions. Journal of the American Statistical Association 1996, 91:1400-1412.
62. Gelman A., Rubin D.B. Markov chain Monte Carlo methods in biostatistics. Statistical Methods in Medical Research 1996, 5:339-355.
63. Gentry P.R., Hack C.E., Haber L., Maier A., Clewell H.J. An approach for the quantitative consideration of genetic polymorphism data in chemical risk assessment: examples with warfarin and parathion. Toxicological Sciences 2002, 70:120-139.
64. Gerlowski L.E., Jain R.K. Physiologically based pharmacokinetic modeling: principles and applications. Journal of Pharmaceutical Sciences 1983, 72:1103-1127.
65. Ghibellini G., Leslie E.M., Brouwer K.L. Methods to evaluate biliary excretion of drugs in humans: an updated review. Molecular Pharmaceutics 2006, 3:198-211.
66. Ghibellini G., Vasist L.S., Leslie E.M., Heizer W.D., Kowalsky R.J., Calvo B.F., Brouwer K.L. In vitro-in vivo correlation of hepatobiliary drug clearance in humans. Clinical Pharmacology and Therapeutics 2007, 81:406-413.
67. Gibaldi M., Perrier D. Pharmacokinetics 1982, Marcel Dekker, New York.
68. Grandison M.K., Boudinot F.D. Age-related changes in protein binding of drugs: implications for therapy. Clinical Pharmacokinetics 2000, 38:271-290.
69. Grover A., Benet L. Effects of drug transporters on volume of distribution. The AAPS Journal 2009, 11:250-261.
70. Hack C.E., Chiu W.A., Zhao Q.J., Clewell H.J. Bayesian population analysis of a harmonized physiologically based pharmacokinetic model of trichloroethylene and its metabolites. Regulatory Toxicology and Pharmacology 2006, 46:63-83.
71. Hadgraft J., Guy R.H. Feasibility assessment in topical and transdermal delivery: mathematical models and in vitro studies. Transdermal Drug Delivery 2003, 1-24. Marcel Dekker, New York. R.H. Guy, J. Hadgraft (Eds.).
72. Hilgendorf C., Ahlin G., Seithel A., Artursson P., Ungell A.L., Karlsson J. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metabolism and Disposition 2007, 35:1333-1340.
73. Ho R.H., Kim R.B. Transporters and drug therapy: implications for drug disposition and disease. Clinical Pharmacology and Therapeutics 2005, 78:260-277.
74. Houston J.B. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochemical Pharmacology 1994, 47:1469-1479.
75. Howgate E.M., Rowland Yeo K., Proctor N.J., Tucker G.T., Rostami-Hodjegan A. Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability. Xenobiotica 2006, 36:473-497.
76. Iwatsubo T., Suzuki H., Sugiyama Y. Prediction of species differences (rats, dogs, humans) in the in vivo metabolic clearance of YM796 by the liver from in vitro data. The Journal of Pharmacology and Experimental Therapeutics 1997, 283:462-469.
77. Jackson P.R., Tucker G.T. Pharmacokinetic-pharmacogenetic modelling in the detection of polymorphisms in xenobiotic metabolism. Annals of Occupational Hygiene 1990, 34:653-662.
78. Jackson P.R., Tucker G.T., Lennard M.S., Woods H.F. Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices. British Journal of Clinical Pharmacology 1986, 22:541-550.
79. Jackson P.R., Tucker G.T., Woods H.F. Backtracking booze with Bayes - the retrospective interpretation of blood alcohol data. British Journal of Clinical Pharmacology 1991, 31:55-63.
80. Jamei M., Dickinson G.L., Rostami-Hodjegan A. A framework for assessing interindividual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of 'bottom-up' vs 'top-down' recognition of covariates. Drug Metabolism and Pharmacokinetics 2009, 24:53-75.
81. Jamei M., Turner D., Yang J., Neuhoff S., Polak S., Rostami-Hodjegan A., Tucker G. Population-based mechanistic prediction of oral drug absorption. The AAPS Journal 2009, 11:225-237.
82. Johanson G. Modelling of respiratory exchange of polar solvents. Annals of Occupational Hygiene 1990, 35:323-339.
83. Johanson G., Jonsson F., Bois F.Y. Development of new technique for risk assessment using physiologically based toxicokinetic models. American Journal of Industrial Medicine 1999, 36(Suppl. 1):101-103.
84. Jonsson F., Bois F.Y., Johanson G. Assessing the reliability of PBPK models using data from methyl chloride-exposed, non-conjugating human subjects. Archives of Toxicology 2001, 75:189-199.
85. Jonsson F., Bois F.Y., Johanson G. Physiologically based pharmacokinetic modeling of inhalation exposure of humans to dichloromethane during moderate to heavy exercise. Toxicological Sciences 2001, 59:209-218.
86. Jonsson F., Johanson G. A Bayesian analysis of the influence of GSTT1 polymorphism on the cancer risk estimate for dichloromethane. Toxicology and Applied Pharmacology 2001, 174:99-112.
87. Jonsson F., Johanson G. Bayesian estimation of variability in adipose tissue blood flow in man by physiologically based pharmacokinetic modeling of inhalation exposure to toluene. Toxicology 2001, 157:177-193.
88. Jonsson F., Johanson G. The Bayesian population approach to physiological toxicokinetic-toxicodynamic models - an example using the MCSim software. Toxicology Letters 2003, 138:143-150.
89. Koepsell H. Organic cation transporters in intestine, kidney, liver, and brain. Annual Review of Physiology 1998, 60:243-266.
90. Koepsell H., Lips K., Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharmaceutical Research 2007, 24:1227-1251.
91. Krüse J., Golden D., Wilkinson S., Williams F., Kezic S., Corish J. Analysis, interpretation, and extrapolation of dermal permeation data using diffusion-based mathematical models. Journal of Pharmaceutical Sciences 2007, 96:682-703.
92. Lee W., Kim R.B. Transporters and renal drug elimination. Annual Review of Pharmacology and Toxicology 2004, 44:137-166.
93. Lin J.H., Sugiyama Y., Awazu S., Hanano M. In vitro and in vivo evaluation of the tissue-to-blood partition coefficient for physiological pharmacokinetic models. Journal of Pharmacokinetics and Biopharmacology 1982, 10:637-647.
94. Lin J.H., Sugiyama Y., Awazu S., Hanano M. Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtained in vitro as well as on physiological data. Journal of Pharmacokinetics and Biopharmacology 1982, 10:649-661.
95. Löf A., Johanson G. Toxicokinetics of organic solvents: a review of modifying factors. Critical Reviews in Toxicology 1998, 28:571-650.
96. Loizou, G., Spendiff, M., Barton, H.A., Bessems, J., Bois, F.Y., Bouvier d'Yvoire, M., Buist, H., Clewell, H.J.III, Meek, B, Gundert-Remy, U., Goerlitz, G., Schmitt, W., 2008. Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps. Regulatory Toxicology and Pharmacology 50, 400-411.
97. ® based general PBPK/PD modeling software. Computers in Biology and Medicine 2008, 38:962-978.
98. Lyons M.A., Yang R.S.H., Mayeno A.N., Reisfeld B. Computational toxicology of chloroform: reverse dosimetry using Bayesian inference, Markov chain Monte Carlo simulation, and human biomonitoring data. Environmental Health Perspectives 2008, 116:1040-1046.
99. Mallet A., Mentre F., Steimer J.L., Lokiec F. Nonparametric maximum likelihood estimation for population pharmacokinetics, with application to cyclosporine. Journal of Pharmacokinetics and Biopharmacology 1988, 16:311-327.
100. Marino D.J., Clewell H., Gentry P., Covington T., Hack C., David R., Morgott D. Revised assessment of cancer risk to dichloromethane: part I Bayesian PBPK and dose-response modeling in mice. Regulatory Toxicology and Pharmacology 2006, 45:44-54.
101. Marino D.J., Starr T.B. Probabilistic dose-response modeling: case study using dichloromethane PBPK model results. Regulatory Toxicology and Pharmacology 2007, 49:285-300.
102. McCarley K.D., Bunge A.L. Pharmacokinetic models of dermal absorption. Journal of Pharmaceutical Sciences 2001, 90:1699-1719.
103. Mezzetti M., Ibrahim J.G., Bois F.Y., Ryan L.M., Ngo L., Smith T.J. A Bayesian compartmental model for the evaluation of 1,3-butadiene metabolism. Journal of the Royal Statistical Society Series C 2003, 52:291-305.
104. Morse M., Cassels D.E., Schlutz F.W. Blood volumes of normal children. American Journal of Physiology 1947, 151:448-458.
105. Morse M., Cassels D.E., Schultz F.W. Available and interstitial fluid volumes of normal children. American Journal of Physiology 1947, 151:438-447.
106. Mouly S., Paine M.F. P-glycoprotein increases from proximal to distal regions of human small intestine. Pharmaceutical Research 2003, 20:1595-1599.
107. Murakami T., Takano M. Intestinal efflux transporters and drug absorption. Expert Opinion on Drug Metabolism & Toxicology 2008, 4:923-939.
108. Nestorov I. Modelling and simulation of variability and uncertainty in toxicokinetics and pharmacokinetics. Toxicology Letters 2001, 120:411-420.
109. Nestorov I. Whole body pharmacokinetic models. Clinical Pharmacokinetics 2003, 42:883-908.
110. Nestorov I. Whole-body physiologically based pharmacokinetic models. Expert Opinion on Drug Metabolism & Toxicology 2007, 3:235-249.
111. Nong A., Tan Y.M., Krolski M.E., Wang J.S., Lunchick C., Conolly R.B., Clewell H.J. Bayesian calibration of a physiologically based pharmacokinetic/pharmacodynamic model of carbaryl cholinesterase inhibition. Journal of Toxicology and Environmental Health - Part a - Current Issues 2008, 71:1363-1381.
112. Obach R.S. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metabolism and Disposition 1999, 27:1350-1359.
113. Paine M.F., Hart H.L., Ludington S.S., Haining R.L., Rettie A.E., Zeldin D.C. The human intestinal cytochrome P450 "Pie" Drug Metabolism and Disposition 2006, 34:880-886.
114. Paine M.F., Khalighi M., Fisher J.M., Shen D.D., Kunze K.L., Marsh C.L., Perkins J.D., Thummel K.E. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. The Journal of Pharmacology and Experimental Therapeutics 1997, 283:1552-1562.
115. Pang K.S. Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series). Drug Metabolism and Disposition 2003, 31:1507-1519.
116. Parrott N., Jones H., Paquereau N., Lavé T. Application of full physiological models for pharmaceutical drug candidate selection and extrapolation of pharmacokinetics to man. Basic and Clinical Pharmacology and Toxicology 2005, 96:193-196.
117. Patton J.S., Byron P.R. Inhaling medicines: delivering drugs to the body through the lungs. Nature Reviews | Drug Discovery 2007, 6:67-74.
118. Péry A., Brochot C., Hoet P., Nemmar A., Bois F.Y. Development of a physiologically-based kinetic model for 99m-technetium labelled carbon nanoparticles inhaled by humans. Inhalation Toxicology 2009, 21:1099-1107.
119. Portier C.J., Kaplan N.L. Variability of safe dose estimates when using complicated models of the carcinogenic process. Fundamental and Applied Toxicology 1989, 13:533-544.
120. Potts R.O., Guy R.H. Predicting skin permeability. Pharmaceutical Research 1992, 9:663-669.
121. Poulin P., Schoenlein K., Theil F.P. Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs. Journal of Pharmaceutical Sciences 2001, 90:436-447.
122. Poulin P., Theil F.P. A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. Journal of Pharmaceutical Sciences 2000, 89:16-35.
123. Poulin P., Theil F.P. Prediction of pharmacokinetics prior to in vivo studies 1. Mechanism-based prediction of volume of distribution. Journal of Pharmaceutical Sciences 2002, 91:129-156.
124. Poulin P., Theil F.P. Prediction of pharmacokinetics prior to in vivo studies II. Generic physiologically based pharmacokinetic models of drug disposition. Journal of Pharmaceutical Sciences 2002, 91:1358-1370.
125. Price P.S., Conolly R.B., Chaisson C.F., Gross E.A., Young J.S., Mathis E.T., Tedder D.R. Modeling interindividual variation in physiological factors used in PBPK models of humans. Critical Reviews in Toxicology 2003, 33:469-503.
126. Proctor N.J., Tucker G.T., Rostami-Hodjegan A. Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica 2004, 34:151-178.
127. Qiu J., Chien Y.C., Bruckner J.V., Fisher J.W. Bayesian analysis of a physiologically based pharmacokinetic model for perchloroethylene in humans. Journal of Toxicology and Environmental Health 2010, 73:74-91.
128. Racine-Poon A., Smith A.F.M. Population models. Statistical Methodology in the Pharmaceutical Sciences 1990, 139-162. Dekker, New York. D.A. Berry (Ed.).
129. Rane A., Wilkinson G.R., Shand D.G. Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. The Journal of Pharmacology and Experimental Therapeutics 1977, 200:420-424.
130. Riley R.J., McGinnity D.F., Austin R.P. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metabolism and Disposition 2005, 33:1304-1311.
131. Ripley B.D. Stochastic Simulation 1987, John Wiley and Sons, New York.
132. Rodgers T., Leahy D., Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. Journal of Pharmaceutical Sciences 2005, 94:1259-1276.
133. Rodgers T., Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. Journal of Pharmaceutical Sciences 2006, 95:1238-1257.
134. Rostami-Hodjegan A., Jackson P.R., Tucker G.T. Sensitivity of indirect metrics for assessing "rate" in bioequivalence studies - moving the "goalposts" or changing the "game" Journal of Pharmaceutical Sciences 1994, 83:1554-1557.
135. Rostami-Hodjegan A., Nurminen S., Jackson P.R., Tucker G.T. Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics 1996, 6:121-149.
136. Rostami-Hodjegan A., Tucker G.T. The effects of portal shunts on intestinal cytochrome P450 3A activity. Hepatology 2002, 35:1549-1550.
137. Rostami-Hodjegan A., Tucker G.T. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nature Reviews Drug Discovery 2007, 6:140-148.
138. Rowland, M., Balant, L., Peck, C., 2004. Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29-30, 2002). AAPS PharmSci 6, E6.
139. Rowland M., Tozer T.N. Clinical Pharmacokinetics: Concepts and Applications 1995, Williams & Wilkins, Baltimore; London.
140. Sato A. The effect of environmental factors on the pharmacokinetic behaviour of organic solvent vapours. The Annals of Occupational Hygiene 1991, 35:525-541.
141. Sawada Y., Hanano M., Sugiyama Y., Harashima H., Iga T. Prediction of the volumes of distribution of basic drugs in humans based on data from animals. Journal of Pharmacokinetics and Biopharmacology 1984, 12:587-596.
142. Schaefer U.F., Hansen S., Schneider M., Contreras J.L., Lehr C.-M. Models for skin absorption and skin toxicity testing. Drug Absorption Studies 2008, 3-33. Springer, New-York, N-Y. C. Ehrhardt, K.-J. Kim (Eds.).
143. Sheiner L.B. The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. Drug Metabolism Reviews 1984, 15:153-171.
144. Smith A.F.M., Wakefield J. The hierarchical Bayesian approach to population pharmacokinetic modelling. International Journal of Bio-Medical Computing 1994, 36:35-42.
145. Spear R.C., Bois F.Y., Woodruff T., Auslander D., Parker J., Selvin S. Modeling benzene pharmacokinetics across three sets of animal data: parametric sensitivity and risk implications. Risk Analysis 1991, 11:641-654.
146. Tett S.E., Kirkpatrick C.M., Gross A.S., McLachlan A.J. Principles and clinical application of assessing alterations in renal elimination pathways. Clinical Pharmacokinetics 2003, 42:1193-1211.
147. Thirup P. Haematocrit: within-subject and seasonal variation. Sports Medicine 2003, 33:231-243.
148. Tsuji A., Tamai I. Carrier-mediated intestinal transport of drugs. Pharmaceutical Research 1996, 13:963-977.
149. Tucker G.T. Measurement of the renal clearance of drugs. British Journal of Clinical Pharmacology 1981, 12:761-770.
150. Vicini P., Pierce C.H., Dills R.L., Morgan M.S., Kalman D.A. Individual prior information in a physiological model of H- 2(8)-toluene kinetics: an empirical Bayes estimation strategy. Risk Analysis 1999, 19:1127-1134.
151. von Richter O., Burk O., Fromm M.F., Thon K.P., Eichelbaum M., Kivisto K.T. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clinical Pharmacology and Therapeutics 2004, 75:172-183.
152. Wakefield J., Bennett J. The Bayesian modeling of covariates for population pharmacokinetic models. Journal of the American Statistical Association 1996, 91:917-927.
153. Wang Z.J., Yin O.Q., Tomlinson B., Chow M.S. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics 2008, 18:637-645.
154. Wilkinson G.R. Clearance approaches in pharmacology. Pharmacological Reviews 1987, 39:1-47.
155. Williams L.R., Leggett R.W. Reference values for resting blood flow to organs of man. Clinical Physics and Physiological Measurement 1989, 10:187-217.
156. Willmann S., Edginton A.N., Kleine-Besten M., Jantratid E., Thelen K., Dressman J.B. Whole-body physiologically-based pharmacokinetic population modelling of oral drug administration: inter-individual variability of cimetidine absorption. Journal of Pharmacy and Pharmacology 2009, 61:891-899.
157. Willmann S., Höhn K., Edginton A., Sevestre M., Solodenko J., Weiss W., Lippert J., Schmitt W. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. Journal of Pharmacokinetics and Pharmacodynamics 2007, 34:401-431.
158. Woodruff T., Bois F.Y. Optimization issues in physiological toxicokinetic modeling - a case study with benzene. Toxicology Letters 1993, 69:181-196.
159. Woodruff T., Bois F.Y., Auslander D., Spear R. Structure and parametrization of toxicokinetic models: their impact on model predictions. Risk Analysis 1992, 12:189-201.
160. Yang J., Jamei M., Yeo K.R., Tucker G.T., Rostami-Hodjegan A. Prediction of intestinal first-pass drug metabolism. Current Drug Metabolism 2007, 8:676-684.
161. Yang J., Rostami-Hodjegan A., Tucker G.T. Prediction of Ketoconazole Interaction with Midazolam, Alprazolam and Triazolam: Incorporating Population Variability 2001, Blackwell Science Ltd., Dublin, Ireland, (pp. 472P-473P).
162. Yu J.-Y., Rosania G. Cell-based multiscale computational modeling of small molecule absorption and retention in the lungs. Pharmaceutical Research 2010, 27:457-467.
163. Yu L.X., Amidon G.L. A compartmental absorption and transit model for estimating oral drug absorption. International Journal of Pharmaceutics 1999, 186:119-125.
164. Yu L.X., Crison J.R., Amidon G.L. Compartmental transit and dispersion model analysis of small intestinal transit flow in humans. International Journal of Pharmaceutics 1996, 140:111-118.